LXRX News and Press, Lexicon Pharmaceuticals Inc.

THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...

2024-07-16 10:02:02 ET More on Lexicon Pharmaceuticals Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Call Transcript Lexicon appoints Mike Exton as CEO, Jeff Wade as COO Lexicon resubmits ...

Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...

New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM) Findings consistent with two peer-reviewed studies published in June 2024 THE WOODLANDS, Texa...

2024-07-12 12:15:26 ET More on ChargePoint Holdings, Tupperware ChargePoint: A Contrarian EV Play For Growth Investors ChargePoint: Struggles Remain Persistent ChargePoint's Management Is Too Optimistic About The Future ChargePoint appoints Mansi Khetani CFO ...

2024-07-08 13:11:29 ET More on Lexicon Pharmaceuticals Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Call Transcript Lexicon resubmits FDA application for sotagliflozin for type 1 diabetes ...

THE WOODLANDS, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Lexicon Board of Directors has appointed Mike Exton, Ph.D. as chief executive officer and director of Lexicon. Dr. Exton succeeds Lonnel Coats who, as previously a...

2024-06-21 10:07:49 ET More on Lexicon Pharmaceuticals Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Call Transcript Lexicon Pharmaceuticals Q1 2024 Earnings Preview Seeking Alpha’s...

Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease Company Anticipates Six Month Review and Potential Launch in Early 2025 THE WOODLANDS, Texas, June 21, 2024 (GLOBE NEWSWIR...

Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP) Investigators conclude that clinical outcomes of RELIEF-DPN 1 support commencement of Lexiconȁ...